COVID-19 vaccine: Sputnik V shows 91.4% efficacy rates again, new data reveals
- The new results are based on data from 22,714 participants in the trial
- Sputnik V has a unique set of parameters making it one of the most competitive vaccines globally, said researchers
Russia's experimental coronavirus vaccine Sputnik V is 91.4% effective in protecting people from COVID-19, according to final interim data by the Gamaleya National Centre National and the Russian Direct Investment Fund on Wednesday. The new results are based on data from 22,714 participants in the trial, and were published after 78 confirmed coronavirus cases were reported among the group, said researchers at the Gamaleya Institute said in a statement. Over 26,000 have been vaccinated in double-blind, randomized, placebo-controlled Phase III of Sputnik V clinical trials.
Login to enjoy exclusive benefits!
- Unlocked premium articles
- Personalized news
- Market Watchlist
- Insightful Newsletters & more